A new antibody has shown potential as treatment for HIV with a mid-stage trial showing it suppressed the virus for up to four months after patients stopped taking antiretroviral medicines.<
The FDA has approved ViiV’s Dovato, a single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine for treatment-naïve patients, making it the only company to have such a drug on